Peer-influenced content. Sources you trust. No registration required. This is HCN.

The New England Journal of MedicineNeoadjuvant–Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma

Event-free survival was significantly longer in patients with resectable stage III or IV melanoma who received pembrolizumab both before and after surgery than in those who received adjuvant pembrolizumab alone. New toxic effects were not discovered.

The Healthcare Communications Network is owned and operated by IQVIA Inc.

Click below to leave this site and continue to IQVIA’s Privacy Choices form